BioSpecifics Technologies announced positive results from its Phase 3b MULTICORD study evaluating Xiaflex (collagenase clostridium histolyticum) for the concurrent treatment of adult Dupuytren’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results